Can you provide the average price target for INSMED INC stock?
26 analysts have analysed INSM and the average price target is 216.16 USD. This implies a price increase of 59.91% is expected in the next year compared to the current price of 135.17.
INSMED INC (INSM) Forecast, Price Target & Analyst Ratings
NASDAQ:INSM • US4576693075
Current stock price
135.17 USD
-8.66 (-6.02%)
At close:
135.17 USD
0 (0%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INSMED INC (INSM).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.98
- Revenue Estimate
- 308.68M
Price Target Details & History
Consensus Price Target and Range
Mean target
$216.16
Upside
+ 59.91%
From current price of $135.17 to mean target of $216.16, Based on 26 analyst forecasts
Low
$178.77
Median
$216.24
High
$255.15
Price Target Revisions
1 Month
-0.06%
3 Months
-0.79%
Price Target Summary
26 Wall Street analysts provided a forecast for the next 12 months for INSM. The average price target is 216.16 USD. This implies a price increase of 59.91% is expected in the next year compared to the current price of 135.17.
The average price target has been revised downward by 0.79% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.15%
INSM was analyzed by 26 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about INSM.
In the previous month the buy percentage consensus was at a similar level.
INSM was analyzed by 26 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-04-17 | Roth Capital | Reiterate | Buy -> Buy |
| 2026-04-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-04-01 | Barclays | Maintains | Overweight -> Overweight |
| 2026-03-30 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2026-03-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-03-25 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-03-24 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2026-03-24 | Stifel | Maintains | Buy -> Buy |
| 2026-03-24 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-03-24 | B of A Securities | Maintains | Buy -> Buy |
| 2026-03-23 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-24 | Mizuho | Maintains | Outperform -> Outperform |
| 2026-02-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2026-02-20 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-01-30 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-28 | Barclays | Initiate | Overweight |
| 2026-01-23 | Roth Capital | Initiate | Buy |
| 2026-01-21 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-01-06 | UBS | Maintains | Buy -> Buy |
| 2025-12-18 | TD Cowen | Maintains | Buy -> Buy |
| 2025-12-18 | Guggenheim | Maintains | Buy -> Buy |
| 2025-12-18 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-12-18 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-12-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-12-16 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.98
- Revenue Estimate
- 308.68M
- Revenue Q2Q
- 232.55%
- EPS Q2Q
- 31.13%
- Number of Analysts
- 20
Next Earnings Revisions
Revenue (1 Month)
0.84%
Revenue (3 Months)
30.26%
EPS (1 Month)
1.81%
EPS (3 Months)
7.89%
Next Earnings Summary
INSM is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.98 USD and the consensus revenue estimate is 308.68M USD.
The next earnings revenue estimate has been revised upward by 30.26% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 305.208M 24.37% | 363.707M 19.17% | 606.423M 66.73% | 1.712B 182.31% | 2.828B 65.19% | 4.102B 45.05% | 5.287B 28.89% | 6.606B 24.95% | 8.27B 25.19% | 9.902B 19.73% | 11.433B 15.46% | |
| EBITDA YoY % growth | -667.638M -43.33% | -772.845M -15.76% | -975.614M -26.24% | -622.689M 36.17% | 159.35M 125.59% | 929.55M 483.34% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -680.929M -42.42% | -786.57M -15.51% | -994.776M -26.47% | -594.32M 40.26% | 181.16M 130.48% | 1.083B 497.81% | 2.083B 92.34% | 2.909B 39.65% | 4.172B 43.42% | 5.469B 31.09% | 6.596B 20.61% | |
| Operating Margin | -223.10% | -216.26% | -164.04% | -34.71% | 6.41% | 26.40% | 39.40% | 44.04% | 50.45% | 55.23% | 57.69% | |
| EPS YoY % growth | -5.34 -36.92% | -5.59 -4.68% | -6.41 -14.67% | -2.95 53.93% | 0.69 123.31% | 3.91 468.24% | 7.84 100.41% | 10.72 36.72% | 15.03 40.18% | 18.88 25.65% | 22.78 20.64% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | Q1 / 28 | Q2 / 28 | Q3 / 28 | Q4 / 28 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.98 31.13% | -0.83 51.34% | -0.64 63.68% | -0.46 69.87% | -0.27 72.88% | -0.09 88.90% | 0.03 104.81% | 0.15 131.51% | 0.22 184.62% | 0.37 500.00% | 0.51 1,566.67% | 0.64 339.55% |
| Revenue Q2Q % growth | 308.68M 232.55% | 381.92M 255.56% | 457.27M 221.25% | 555.03M 110.36% | 507.57M 64.43% | 568.07M 48.74% | 620.66M 35.73% | 655.82M 18.16% | 810.6M 59.70% | 863.45M 52.00% | 919.4M 48.13% | 973.64M 48.46% |
| EBITDA Q2Q % growth | -210.436M 6.89% | -174.925M 28.78% | -138.929M 44.08% | -62.654M 72.82% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -199.766M 13.08% | -163.7M 35.52% | -122.678M 53.06% | -69.583M 72.13% | -32.385M 83.79% | 7.344M 104.49% | 20.655M 116.84% | 33.711M 148.45% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
37.69%
EPS Next 5 Year
29.72%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
98.59%
Revenue Next 5 Year
66.02%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
40.57%
EBIT Next 5 Year
N/A
INSMED INC / INSM Forecast FAQ
Can you provide the upcoming earnings date for INSMED INC?
INSMED INC (INSM) will report earnings on 2026-05-06.
Can you provide the consensus estimates for INSMED INC next earnings?
The consensus EPS estimate for the next earnings of INSMED INC (INSM) is -0.98 USD and the consensus revenue estimate is 308.68M USD.
What is the expected long term growth rate for INSM stock?
The expected long term growth rate for INSMED INC (INSM) is 98.59%.